Search
United Therapeutics Corp
UTHRAdd to Watchlist
544.330USD
+6.030+1.12%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
22.95BMarket Cap
18.60P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of United Therapeutics Corp is 8.13, ranking 52 out of 157 in the Pharmaceuticals industry. The average price target is 525.00, with a high of 600.00 and a low of 410.43.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
668.017
Target Price
+24.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
United Therapeutics Corp
UTHR
16
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is United Therapeutics Corp's expected revenue for the next quarter?
United Therapeutics Corp's expected revenue is 808.70M.
What is United Therapeutics Corp's price target?
Analysts forecast that United Therapeutics Corp's price target is USD 525.00, with the highest forecast at USD 600.00 and the lowest forecast at USD 410.43.
How have United Therapeutics CorpUTHR's recent earnings per share performed?
The market expectation was USD 6.32, while United Therapeutics CorpUTHR's earnings per share (EPS) for the previous quarter was USD 8.39. EPS for the next quarter is expected at USD 7.11.
What is the analyst rating for United Therapeutics Corp?
Based on the ratings of United Therapeutics Corp's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
